Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00522145 · ClinicalTrials.gov registry record · Phase 2
Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib
A Phase 2 study of Carcinoma, Non-Small Cell Lung, sponsored by Kadmon Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 10
- Study locations
NCT00522145: Completed Phase 2 study of Carcinoma, Non-Small Cell Lung, sponsored by Kadmon Corporation.
NCT00522145 is a Phase 2 study of Carcinoma, Non-Small Cell Lung that has completed, run by Kadmon Corporation. The registered enrollment target is 41 participants, below the 324-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (87% lower). The trial reports 10 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00522145, a Phase 2 study of Carcinoma, Non-Small Cell Lung, has completed, sponsored by Kadmon Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to determine the best confirmed response rate of daily administration of the multiple receptor tyrosine kinase (RTK) inhibitor (including EGFR and VEGFR2) XL647 in subjects with NSCLC who have progressed after responding to treatment with either erlotinib or gefitinib.
Conditions Studied
Interventions
- DRUG XL647
Study Locations (10)
California
- Ronald Yanagihara - Gilroy
- University of California Davis Cancer Center - Sacramento
- Oncology Division and General Clincial Research, Stanford University Medical Center - Stanford
Ohio
- Case Western Reserve University, University Hospitals of Cleveland - Cleveland
- Signal Point Clinical Research Center - Middletown
Indiana
- Cancer Care Center, Inc. P.C. - New Albany
Maryland
- Washington County Hospital, The Center for Clinical Research - Hagerstown
Michigan
- Wayne State University, Wertz Clinical Cancer Center, Karmanos Center - Detroit
New York
- Memorial Sloan-Kettering Cancer Center - New York
North Carolina
- New Bern Cancer Care Oncology - New Bern
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2007-05 |
| Est. Completion | 2010-02 |
| Phase | Phase 2 |
What the finished NCT00522145 record still lists
NCT00522145 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 324-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 1 intervention - of which XL647 is the first listed.
NCT00522145 lists 10 locations in 7 states (California, Ohio, Indiana).
Frequently Asked Questions
What is clinical trial NCT00522145 about?
NCT00522145 is a clinical study titled "Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib". The purpose of this study is to determine the best confirmed response rate of daily administration of the multiple receptor tyrosine kinase (RTK) inhibitor (including EGFR and VEGFR2) XL647 in subjects with NSCLC who have progressed after responding to treatment with either erlotinib or gefitinib.
What is the current status of trial NCT00522145?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2007-05. Estimated completion is 2010-02.
What conditions does trial NCT00522145 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.
What interventions are being tested in trial NCT00522145?
The interventions under investigation include: XL647 (DRUG).
Who is sponsoring clinical trial NCT00522145?
This trial is sponsored by Kadmon Corporation, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00522145 being conducted?
This trial has 10 study locations across California, Indiana, Maryland, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00522145's enrollment target sits among peer trials
41 100th of 130 higher than 31 of 130 other Carcinoma, Non-Small Cell Lung trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
RECRUITING · Phase 2
-
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
RECRUITING · Phase 2
-
Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy
RECRUITING · Phase 2
-
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
RECRUITING · Phase 2
-
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
RECRUITING · Phase 2
-
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia